Enliven Therapeutics, Inc. (ELVN) — 10-Q Filings
All 10-Q filings from Enliven Therapeutics, Inc.. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (5)
-
Enliven Narrows Q3 Loss, Boosts Cash with $216M Public Offering
— Nov 12, 2025 Risk: high
Enliven Therapeutics, Inc. (ELVN) reported a net loss of $20.148 million for the three months ended September 30, 2025, an improvement from the $23.156 million -
Enliven Therapeutics Files Q1 2025 10-Q
— May 14, 2025 Risk: medium
Enliven Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as IMARA Inc., reported financial information for th -
Enliven Therapeutics Files Q3 2024 10-Q
— Nov 13, 2024 Risk: medium
Enliven Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial position and results of operations. Key f -
Enliven Therapeutics Files Q2 2024 10-Q
— Aug 13, 2024 Risk: medium
Enliven Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly IMARA Inc., reported financial results and operational upda -
Enliven Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024
— May 14, 2024 Risk: low
Enliven Therapeutics, Inc. (ELVN) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Enliven Therapeutics, Inc. filed a 10-Q report for the period en
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX